Overview
Mission Therapeutics is a clinical-stage biopharmaceutical company specializing in the discovery and development of small-molecule deubiquitylating enzyme (DUB) inhibitors to treat serious diseases characterized by mitochondrial dysfunction. The company's lead program targets USP30, a mitochondrial DUB that inhibits mitophagy—the cellular quality control process responsible for removing damaged mitochondria. By selectively inhibiting USP30, Mission's therapeutics aim to restore normal mitochondrial function and cellular health across multiple disease indications including Parkinson's disease, heart failure, Duchenne muscular dystrophy, and other neurodegenerative and mitochondrial disorders. Mission's proprietary DUB platform combines novel disease biology, bespoke screening tools, and unique chemistry to generate a pipeline of highly potent and selective candidates with substantial clinical and commercial potential.